Bidutam 0.5 mg/0.4 mg hard capsules EFG
Dutasteride/tamsulosin hydrochloride
Read this prospectus carefully before starting to take this medicine, as it contains important information for you.
This medicationis used in men to treat an enlarged prostate(benign prostatic hyperplasia)- a non-cancerous growth of the prostate caused by producing an excess of a hormone called dihydrotestosterone.
This medication is a combination of two different medications called dutasteride and tamsulosin. Dutasteride belongs to a group of medications called5-alpha reductase inhibitorsand tamsulosin belongs to a group of medications calledalpha blockers.
As the prostate grows in size, it can produce urinary problems such as difficulty in urinating and a need to urinate more frequently. It can also cause the urine stream to be smaller and less forceful. If benign prostatic hyperplasia is not treated, there is a risk of the urine flow being completely blocked(acute urinary retention). This requires immediate medical treatment. In some cases, surgery may be necessary to reduce the size of the prostate or remove it.
Dutasteride reduces the production of dihydrotestosterone, which helps to reduce the size of the prostate and alleviate symptoms. This reduces the risk of acute urinary retention and the need for surgery. Tamsulosin acts by relaxing the muscles of the prostate, making urination easier and rapidly improving symptoms.
Do not takeBidutam
Warnings and Precautions
Consult your doctor before starting to take this medication.
Consult your doctor or pharmacistif you have any doubts about the administration of this medication.
Other medications and Bidutam
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Do not take dutasteride/tamsulosin with these medications:
Do not take this medication with these medications:
Certain medications may interact with this medication, which may cause you to experience adverse effects. Some of these medications are:
Inform your doctorif you are taking any of these medications.
Taking Bidutam with food and drinks
You should take this medication 30 minutes after the same meal every day.
Pregnancy, breastfeeding, and fertility
This medication should not be taken by women.
Pregnant women (or those who may be pregnant) should avoid contact with broken capsules. Dutasteride is absorbed through the skin and may affect the normal development of the male fetus. This risk is especially important in the first 16 weeks of pregnancy.
Consult your doctorif a pregnant woman has been in contact with Bidutam.
Use a condom during sexual intercourse.Dutasteride has been found in the semen of men taking dutasteride/tamsulosin. If your partner is pregnant or may be pregnant, you should avoid exposing her to your semen.
Dutasteride/tamsulosin has been shown to decrease sperm count, motility, and semen volume. This may reduce male fertility.
Driving and operating machinery
Some people may experience dizziness during treatment with this medication, which may affect your ability to drive or operate machinery safely.
Do not drive or operate machineryif you are affected in this way.
Bidutam containssoy lecithin, yellow orange S (E110), and sodium
This medication may cause allergic reactions because it contains yellow orange S (E110). It may cause asthma, especially in patients allergic to acetylsalicylic acid.
This medication contains soy lecithin, which may contain soy oil. It should not be used in cases of allergy to peanuts or soy.
This medication contains less than 23 mg of sodium (1 mmol) per capsule; it is essentially "sodium-free".
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist.If you do not take this medication regularly, the control of your PSA levels may be affected. In case of doubt, consult your doctor or pharmacist again.
What dose should you take
The recommended dose is one capsule once a day, 30 minutes after the same meal every day.
How to take it
The capsules should be swallowed whole, with water.Do not chew or break the capsules. Contact with the contents of the capsules may irritate your mouth or throat.
If you take more Bidutam than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Bidutam
Do not take a double dose to compensate for the missed doses. Take the next dose at the usual time.
Do not interrupt Bidutam treatment without advice
Do not interrupt treatment with this medication without consulting your doctor first.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
This medication, like all others, may cause side effects, although not everyone will experience them.
Allergic reaction
The symptoms of an allergic reaction may include:
Contact your doctor immediatelyif you experience any of these symptoms andstop taking this medication.
Dizziness, lightheadedness, and fainting
This medication may cause dizziness, lightheadedness, and, in rare cases, fainting. Be careful when getting up quickly after sitting or lying down, especially if you have to get up during the night, until you know how this medication affects you. If you feel dizzy or experience lightheadedness during treatment,sit or lie down until these symptoms have disappeared.
Severe skin reactions
The signs of severe skin reactions may include:
Contact your doctor immediatelyif you have these symptoms andstop using this medication.
Common side effects (may affect more than 1 in 10 people)
*In a small number of people, some of these adverse events may continue after stopping this medication.
Rare side effects (may affect up to 1 in 1,000 people)
Very rare side effects (may affect up to 1 in 10,000 people)
Other side effects
Other side effects have occurred in a small number of men, but their exact frequency is unknown (the frequency cannot be estimated from the available data):
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging, blister, or bottle after CAD or EXP. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30°C.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and unused medications. By doing so, you will help protect the environment.
Composition of Bidutam
The active principles are dutasteride and hydrochloride of tamsulosin. Each capsule contains 0.5 mg of dutasteride and 0.4 mg of hydrochloride of tamsulosin.
The other components are:
Appearance of the product and contents of the package
This medicine is a hard, oblong capsule, approximately 24 mm in length, with a brown body and an orange cap.
They are available in HDPE bottles or aluminum/aluminum blisters of 30 and 90 capsules.
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
LABORATORIOS Q PHARMA S.L.
C/ Moratín, nº 15, Entlo. Offices 6-7
03008 Alicante
Spain
Responsible manufacturer
SAG MANUFACTURING, S.L.U.
Ctra. N-I, km 36
28750 San Agustín de Guadalix (Madrid)
Spain
GALENICUM HEALTH, S.L.
Sant Gabriel, 50
Esplugues de Llobregat
08950 Barcelona
Spain
This medicine is authorized in the member states of the European Economic Area with the following names:
Malta | Dutasteride/Tamsulosin Q Pharma 0.5mg/0.4mg Hard Caps |
Spain | Bidutam 0.5 mg/0.4 mg hard capsules EFG |
Last review date of this leaflet:February 2020.
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.